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ABSTRACT:
Objective: To determine whether relinquishing cognitive,
physical, and social activities is associated with an increased
risk of cognitive decline in patients with age-related macular
degeneration (AMD).
Design: Three year longitudinal study of 206 nondemented
patients with AMD.
Results: Twenty three subjects (14.4%) declined cognitively.
Age, sex, education, decline in visual acuity, and number of
dropped activities were associated with cognitive decline; each
additional dropped activity increased the risk by 58%. Subjects
who relinquished 3 activities were 3.87 times [95% CI 1.95,
7.76] more likely to become demented than subjects who
relinquished no activities; those who relinquished 5 activities
were 9.54 times [95% CI 3.05, 30.43] more likely. A multivariate
model demonstrated that number of dropped activities was a
powerful predictor of cognitive decline after controlling for
relevant risk factors, particularly for subjects less than 80
years of age.
Conclusion: Relinquishing valued activities is
an increased risk of cognitive decline in older
vision loss due to AMD. These data suggest the
promoting optimal cognitive and physical health
AMD and perhaps other chronic diseases.
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Introduction:
Recent studies suggest that complex mental activity, physical
exercise, and social engagement may prevent cognitive decline in
older persons.1-9 It is uncertain, however, whether medical
conditions that decrease participation in these activities are
associated with cognitive decline. We investigated that
possibility in older persons with age-related macular
degeneration (AMD). AMD is a highly disabling degenerative
disease of the macular region of the retina that leads to
geographic atrophy (one type of dry AMD) or choroidal
neovascularization (wet AMD).10 It is the leading cause of legal
blindness in older persons in the United States, affects more
than 10 million people, and prevents many from reading, driving,
socializing and pursuing hobbies.11-14
Some researchers have noted intriguing relationships between AMD
and Alzheimer’s disease (AD).15 In both conditions, misfolded
amyloid beta peptides accumulate (in the retina and in the
brain, respectively) and may play a central role in their
onset.16 If this is the case, cognitive and vision impairment in
AMD may reflect a shared pathogenesis. Alternatively, vision
loss may lead to cognitive decline via deafferentation of the
visual system from the sensory cortex.17 Vision loss may also
result in behavioral changes (e.g., relinquishing valued
activities like reading and socializing) that indirectly and
adversely affect neural function and can lead to or unmask
incipient cognitive decline.6
In this study, we examined whether relinquishing cognitive,
physical, and/or social activities is associated with an
increased risk of cognitive decline, using data from the
Preventing Depression in AMD Trial.18 This was a 12 month
randomized controlled clinical trial comparing the efficacy of
problem-solving treatment (PST) versus usual care to prevent
depressive disorders in older patients with AMD. At the baseline
visit of the clinical trial, we assessed the extent to which the
206 enrolled subjects had relinquished specific activities that
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other research suggests prevent cognitive decline. Then, 3 years
later, we interviewed the 160 available knowledgeable informants
of subjects who were originally enrolled in the clinical trial
to ascertain whether subjects had declined cognitively. We
tested the hypothesis that relinquishing more valued activities
was associated with an increased risk for cognitive decline.

Background:
We recruited 206 subjects from December 2001 to July 2005 from
the retinovitreous clinics associated with Wills Eye Institute
in Philadelphia, PA, enrolling those with newly diagnosed
neovascular AMD (NV-AMD) in one eye (within the preceding 6
months) and pre-existing AMD in the fellow eye. The other
inclusion criteria were age over 64 years and visual acuity in
the better eye of 20/70 or worse. We chose these parameters to
identify older patients with recent bilateral visual impairment
who were at high risk for vision-related disability. The
exclusion criteria were the presence of DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders) diagnoses of depressive
or other axis I disorders, current treatment for depression,
cognitive impairment, and confounding eye conditions. All
subjects signed an informed consent form approved by Thomas
Jefferson University’s Institutional Review Board.
We reviewed fluorescein angiogram reports, confirmed clinical
diagnoses with treating ophthalmologists, and sent introductory
letters to 602 potentially eligible patients. Of these, 230
(38%) were eligible (based on telephone screening) and were
enrolled in the clinical trial. The major reasons for
nonparticipation were: refusal (242; 40%); inability to contact
(66; 11%); cognitive impairment (18; 3%); depression on
screening (8; 1%) and other (38; 6%). Subjects who did not
participate did not differ from participating subjects on
demographic characteristics, visual acuity nor a screening
measure of depression (data not shown).
We screened for cognitive impairment at baseline for the
clinical trial using an abbreviated version of the Mini-Mental
Status Examination that omits vision-dependent items.19 This
version included orientation to time (i.e., day, month, and
year), spelling “world” backwards, and delayed recall of 3
words. Possible scores ranged from 0 to 11 with higher scores
indicating better cognitive function. To be eligible, subjects
needed to answer the 3 orientation questions correctly, score at
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least 3 of 5 on “world” backwards, and recall 2 of 3 words on
delayed recall. We repeated this version of the Mini-Mental one
year later at the end of the clinical trial.
At baseline, we asked subjects to rate their participation in
(including whether they had relinquished any) complex cognitive
activities, physical exercise, and social engagement using the
corresponding items of the National Eye Institute Vision
Function Questionnaire (NEI VFQ-17).20 We targeted the following
6 activities: reading, exercise/sports, hobbies, spectator
activities, social activities, and cards/games. Each was scored
categorically as to whether the subject continued to engage in
(scored 0) or had relinquished the activity (scored 1). Scores
were summed (range 0 to 6) with higher scores indicating a
greater number of relinquished activities.
Following the baseline assessment, 206 of the 230 (90%) subjects
were randomized to the PST and control groups in a 1:1
allocation ratio. Twenty four subjects were not randomized
because of consent withdrawal (N=19), depression (N=4) or
cognitive impairment (N=1) on further screening. From January
2002 to August 2005, PST-trained therapists administered six
weekly 30-45 minute PST sessions over 8 weeks to PST-assigned
subjects. PST is a manual-driven psychological treatment that
teaches problem-solving skills to define problems, establish
realistic goals, generate and implement solutions, and evaluate
outcomes.27 Subjects in the control condition received usual care
from their ophthalmologists and other health care providers.
Assessments during the Clinical Trial: Research nurses with
extensive training in ophthalmology and psychiatry obtained
informed consent and conducted clinical examinations in
subjects’ homes. Demographic characteristics included age, race,
sex, years of education, and marital status. We assessed bestcorrected distance visual acuity in each eye separately using
the Lighthouse Ferris-Bailey ETDRS Chart at baseline and month
12.21 Scores were converted to the logarithm of the minimum angle
of resolution (logMAR) with higher scores indicating greater
impairment.22 Medical comorbidity was assessed using the Chronic
Disease Score, which is derived from a weighted sum of
medications taken for chronic illness, at baseline and month
12.23 The score predicts health care utilization, costs,
hospitalization rates and mortality with higher scores indicating
greater medical disease burden.24 We created a vascular
conditions variable at baseline (i.e., hypertension, diabetes,
and stroke) to examine as a possible risk factor for cognitive
decline. Incident DSM-IV defined-depressive disorders were
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identified at months 2, 6, and 12 using the Modified Schedule
for Affective Disorders and Schizophrenia and the Structured
Interview Guide for the Hamilton Rating Scale.25,26
Follow-up Informant Interviews after Completion of the Clinical
Trial: From May to September 2006, we administered the Informant
Questionnaire for Cognitive Decline in the Elderly (IQCODE) on
one occasion by telephone to each of the 160 knowledgeable
informants who were available for follow-up.28 The 160 subjects
(76.6% of the 206 subjects enrolled in the clinical trial) on
whom informants provided IQCODE scores did not differ in their
demographic or clinical characteristics (including number of
dropped activities, abbreviated MMSE scores at baseline, and
incidence rates of depressive disorder during the trial) from
the 46 subjects for whom IQCODE scores were unavailable (data
not shown). The average length of time (and standard deviation)
from subjects’ baseline evaluation to the IQCODE administration
was 3.00 (.93) years. The standard deviation reflects the
relatively longer time to enroll the sample (i.e., 3.5 years) in
relation to the 4 month time period during which informants were
interviewed.
The IQCODE measures cognitive decline from a premorbid level
using informant reports (e.g. decline in recalling recent
conversations, knowing the day and month).28 A 16-item short form
of the original 26-item version correlates 0.98 with the full
length version and has equally strong discriminatory power and
internal consistency (alpha 0.93).29 Each of the 16 items is
scored on a 5-point scale from 1-“better than before” to 5-“much
worse” (3=no change). Ratings are averaged to give an overall
score from 1 to 5. Factor analyses show that the IQCODE
measures a single general factor of cognitive decline.28 A
number of studies have demonstrated its reliability and validity
against measures of cognitive change over time, clinical
diagnoses, neuropathology and neuroimaging results.28 Jorm et al
(2004) cited a variety of cut scores in different populations
that maximize sensitivity and specificity: in community
populations, cut-scores range from 3.3-3.6 and in patient
samples from 3.4-4.0.28 None of the samples studied, however,
closely resemble the visually impaired older adults that we
studied. For this reason, we took a conservative, empirical
approach to define an appropriate cut-score that maximized
specificity (to avoid false positives). We defined subjects as
“cognitively impaired” if their IQCODE scores exceeded one
standard deviation above the mean for this population. A cutscore of 3.81 met this criterion.
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Statistical Methods: Due to the variability in follow-up time,
the measure of interest in describing cognitive decline is the
incidence density, which is the number of new cases divided by
the total person years of follow-up. Poisson regression was
used to model the incidence of cognitive decline while adjusting
for different amounts of follow-up time. Generalized Estimating
Equation (GEE) methods were used to adjust standard errors and
p-values.30 Clinically relevant variables were considered
independent predictors of cognitive decline if they had a p
value of 0.10 or less at the bivariate level. A variable was
considered a confounder of the association between dropped
activities and cognitive decline if coefficients of terms in the
model change by more than 15%. A variable was called an effect
modifier if the p-value for the interaction term was less than
0.05.
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Results: The mean age and education (+/- standard deviation) of
the sample was 81.1 (5.8) and 12.5 (3.1) years, respectively;
70% were women; 98.1% were white; and 41.5% lived alone. The
distribution of IQCODE scores was skewed to the right and had
the following characteristics: range 2.63-5.00; median 3.13; and
mean 3.30 (0.51).
Twenty three subjects (14.4% of the sample) met the criterion
for cognitive decline, representing an incidence density of 48.6
cases per 1000 person years at risk. Table 1 presents
descriptive statistics for the sample and the bivariate
relationships between the study measures and dementia status at
follow-up. The relationships are reported as incidence density
ratios, which are based on Poisson regressions with number of
years from the one-year assessment to follow-up as an offset
variable. The Table shows that age, sex, education, change in
visual acuity, and number of dropped activities were associated
with dementia at follow-up: each 5 year increment in age
increased dementia risk by 57%; each 4 year increment of
education increased the risk by 36%; and each additional dropped
activity increased the risk by 57%. Thus, subjects who
relinquished 3 activities, for example, were 3.87 times [95% CI
1.95, 7.76] more likely to become demented than subjects who
relinquished no activities. The risk for subjects who
relinquished 5 activities increased to 9.54 times [95% CI 3.05,
30.43].
Baseline abbreviated MMSE score, visual acuity in the better
eye, medical comorbidity (i.e., Chronic Disease Score), vascular
risk factors, and treatment assignment (PST vs. Usual Care) were
unrelated to dementia risk. During the one year clinical trial,
decline by more than one point on the abbreviated MMSE, incident
depressive disorder, and changes in medical comorbidity were
also unrelated to dementia risk. There was no significant
correlation between number of dropped activities and baseline
abbreviated MMSE (r =.05; p = .525) or change in MMSE scores
from baseline to 12 months (r = 0.10; p = .213).
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Table 2 shows the results of a multivariate model that included
age, number of dropped activities, and their interaction.
Although education, sex, and change in visual acuity were
significant at the bivariate level, when added to the model they
did not meet the criterion for confounding and were thus not
included in the final model. The interaction term of age X
dropped activities was significant (p=0.013), indicating effect
modification by age. For those over age 80, each additional
dropped activity increased the risk of cognitive decline by 27%
(IDR=1.27; 95% CI [0.99, 1.63]; p=0.065). For those under 80,
the effect was stronger; each additional activity dropped
increased the risk of cognitive decline by nearly 200%
(IDR=2.96; 95% CI [1.59, 5.52]; p ≤ 0.001).
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Discussion: We found that relinquishing valued activities was
associated with an increased risk of cognitive decline in
patients with recent bilateral vision loss due to AMD. The
effect was particularly strong in subjects under 80 years of
age, consistent with other studies that have reported a more
aggressive trajectory of decline in younger persons.31-32 .
These findings are best understood, however, in the context of
the study’s limitations. For one, the subjects we studied were
not representative of most patients with AMD or the general
population of older persons; thus, the results may have limited
generalizability. Second, we conducted no formal clinical or
neuropsychological assessments at baseline to accurately
characterize the cognitive function of the sample. At follow-up,
we had no clinical validation of dementia diagnoses or precise
knowledge of the temporal relationship between cognitive decline
and loss of activities. The abbreviated MMSE that we used was
likely insensitive to mild cognitive impairment and may have
misclassified subjects at baseline or was insensitive to change
over time. Other researchers, however, have used similar MMSE
versions and have found equivalent power to distinguish demented
from nondemented individuals. Regarding the IQCODE, although the
validity of the cut score that we used is uncertain, it was more
stringent than is commonly employed. However, we excluded
patients from the study who had a history or objective evidence
of cognitive impairment and found no correlation between
activity loss and cognitive measures at baseline or with
cognitive change over one year. The latter suggests that a
dementing process was not evident at the time of enrollment.
Moreover, the incidence rate of cognitive decline that we
observed is comparable to that reported in similar age cohorts
(ranging from 32.6 to 59.9 cases per 1,000 patient years), which
supports the validity of our findings.33
Nevertheless, we
cannot exclude the possibility that activity loss may well have
represented an early sign of dementia in some subjects.
Alternatively, activity loss may have triggered or hastened the
onset of cognitive decline although the association that we
found between activity loss and cognitive decline does not
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demonstrate this possibility. Epidemiological and clinical
studies have established a link between vision loss and
cognitive decline, however. Crews and Campbell (2004) examined
the 1994 Second Supplement on Aging involving 9,447 older
persons and found that those with self-reported vision loss were
2.2 times more likely to be cognitively impaired than those
without vision loss.34 Reyes-Ortiz et al (2005), using the
population-based Hispanic Established Populations for
Epidemiologic Studies of the Elderly, found that objective
measures of vision impairment were associated with cognitive
decline.35
In patients with AMD, the Age-Related Eye Disease
Study Research Group (2006) found that increased macular
abnormalities and reduced vision were associated with lower
cognitive function and that persons with vision acuity worse
than 20/40 in both eyes were more likely to be cognitively
impaired than persons with better visual acuity.36
The mechanisms linking vision loss, due to AMD in particular,
with cognitive decline are uncertain although existing research
suggests a number of possibilities. AMD and Alzheimer’s disease
(AD), for example, share histopathological features that suggest
a common pathogenesis. Amyloid beta deposition and inflammatory
proteins characterize both ocular drusen and the neuritic
plaques of AD.15 Some studies show that amyloid beta increases
vascular endothelial growth factor (VEGF) and may lead to
retinal pigment epithelium atrophy.16 In AD, amyloid betainduced neurotoxicity appears to be central to
neurodegeneration.35 Moreover, previous studies have observed
degeneration of the optic nerve and retina in Alzheimer’s
disease.37
AMD and AD also share vascular risk factors (e.g.
atherosclerosis) but have different genetic risks (i.e., the APO
Є4 allele increases the risk for AD but decreases the risk for
AMD).38,39
In AD, we know that cognitive activities such as reading or
playing board games or musical instruments have the potential to
reduce the risk of dementia as do physical and social
activities.1-4,7
The mechanism by which these activities
maintain cognition is uncertain but may involve enhancing the
brain’s capacity to tolerate neuropathology (i.e., increased
neural reserve) via beneficial effects upon neuroplasticity,
neurogenesis, or cortisol regulation.40,41
Although other
mechanisms are possible, our finding that activity loss is
associated with cognitive decline in AMD suggests the importance
of maintaining activities in the face of vision loss. This
finding may also apply to patients with other chronic diseases
that lead to the loss of or restrict participation in valued
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activities. If so, promoting optimal cognitive and physical
health may have wide relevance to the care of the growing
population of older adults with chronic disabilities.
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